These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17535081)

  • 21. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
    Dutta S; Reed RC; O'Dea RF
    Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium.
    Reed RC; Dutta S
    Am J Health Syst Pharm; 2004 Nov; 61(21):2284-9. PubMed ID: 15552636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.
    Olsson B; Szamosi J
    Clin Pharmacokinet; 2001; 40(3):227-35. PubMed ID: 11327200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overnight versus progressive conversion of multiple daily-dose divalproex to once-daily divalproex extended release: which strategy is better tolerated by adults with intellectual disabilities?
    Hellings JA; Barth FX; Logan M; Cook-Wiens G; Osorio I; Reed RC
    J Clin Psychopharmacol; 2009 Oct; 29(5):492-5. PubMed ID: 19745651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders.
    Remmerie B; Ariyawansa J; De Meulder M; Coppola D; Berwaerts J
    J Clin Pharmacol; 2016 Jun; 56(6):683-92. PubMed ID: 26412032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania.
    Hirschfeld RM; Bowden CL; Vigna NV; Wozniak P; Collins M
    J Clin Psychiatry; 2010 Apr; 71(4):426-32. PubMed ID: 20361904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
    Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
    J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures.
    Thibault M; Blume WT; Saint-Hilaire JM; Zakhari R; Sommerville KW
    Epilepsy Res; 2002 Aug; 50(3):243-9. PubMed ID: 12200215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
    Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
    Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers.
    Roberts D; Easter D; O'Bryan-Tear G
    Biopharm Drug Dispos; 1996 Mar; 17(2):175-82. PubMed ID: 8907724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxybutynin extended-release: a review of its use in the management of overactive bladder.
    Siddiqui MA; Perry CM; Scott LJ
    Drugs; 2004; 64(8):885-912. PubMed ID: 15059046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials.
    Smith MC; Centorrino F; Welge JA; Collins MA
    Epilepsy Behav; 2004 Oct; 5(5):746-51. PubMed ID: 15380129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).
    Tompson DJ; Ali I; Oliver-Willwong R; Job S; Zhu L; Lemme F; Hammer AE; Vuong A; Messenheimer JA
    Epilepsia; 2008 Mar; 49(3):410-7. PubMed ID: 17825077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol.
    Murthy BP; Skee DM; Danyluk AP; Brett V; Vorsanger GJ; Moskovitz BL
    Curr Med Res Opin; 2007 Feb; 23(2):275-84. PubMed ID: 17288681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended-release divalproex in child and adolescent outpatients with epilepsy.
    Kernitsky L; O'Hara KA; Jiang P; Pellock JM
    Epilepsia; 2005 Mar; 46(3):440-3. PubMed ID: 15730542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steady-state pharmacokinetics of a novel extended-release metformin formulation.
    Timmins P; Donahue S; Meeker J; Marathe P
    Clin Pharmacokinet; 2005; 44(7):721-9. PubMed ID: 15966755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
    Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
    Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.